Financial Performance - Shandong Weigao Group recorded revenue of approximately RMB 13,619,007,000 for the year ended December 31, 2022, representing a growth of 3.1% compared to RMB 13,208,942,000 in 2021[3]. - The net profit attributable to the owners of the company was approximately RMB 2,723,309,000, an increase of 19.7% from RMB 2,275,929,000 in the previous year[3]. - Excluding special items, the net profit attributable to the owners was approximately RMB 2,742,668,000, reflecting a growth of 13.9% compared to RMB 2,407,853,000 in 2021[3]. - Total comprehensive income for the year was RMB 3,250,092,000, compared to RMB 2,376,297,000 in 2021, indicating a significant increase[5]. - The company reported a pre-tax profit of RMB 3,317,901 thousand for the year, up from RMB 2,877,845 thousand in the previous year, indicating a growth of about 15.3%[16][17]. - The company’s net profit for the year ended December 31, 2022, was RMB 2,723,309,000, an increase from RMB 2,275,929,000 in 2021, representing a growth of approximately 19.6%[35]. - The company reported other income of RMB 323,210,000 for the year ended December 31, 2022, compared to RMB 283,438,000 in 2021, an increase of 14.0%[28]. - The income tax expense for the year ended December 31, 2022, was RMB 424,267,000, slightly higher than RMB 420,066,000 in 2021, an increase of 1.0%[32]. - The financing costs for the year ended December 31, 2022, amounted to RMB 191,401,000, up from RMB 140,441,000 in 2021, representing a rise of 36.3%[31]. Dividends and Shareholder Returns - The company proposed a final dividend of RMB 0.079 per share, up from RMB 0.065 per share in the previous year, subject to shareholder approval[3]. - The company declared a total dividend of RMB 690,165,000 for the year, compared to RMB 655,739,000 in the previous year, marking an increase of approximately 5.2%[36]. - The board proposed a final dividend of RMB 0.079 per share for the year ended December 31, 2022, totaling RMB 361,079,995, compared to RMB 0.065 per share and RMB 297,091,101 in the previous year[89]. - The final dividend will be paid in RMB for non-listed domestic shares and H-shares held through the Stock Connect, while other H-share dividends will be paid in HKD[89]. - The record date for the final dividend entitlement is June 8, 2023, with the payment expected to be made on or before July 14, 2023[88]. Assets and Liabilities - The company's total assets less current liabilities amounted to RMB 27,261,403,000 as of December 31, 2022, compared to RMB 25,400,021,000 in the previous year[8]. - Total equity increased to RMB 23,446,603 thousand from RMB 21,047,005 thousand, reflecting a growth of approximately 11.4%[9]. - The total assets of the group increased to RMB 33,195,926 thousand in 2022, up from RMB 30,577,757 thousand in 2021, representing a growth of approximately 5.3%[20]. - The total liabilities for the segments amounted to RMB 9,386,445 thousand in 2022, compared to RMB 9,041,200 thousand in 2021, indicating an increase of about 3.8%[21]. - Non-current liabilities decreased to RMB 3,814,800 thousand from RMB 4,353,016 thousand, a reduction of approximately 12.4%[9]. Research and Development - Research and development expenses increased to RMB 546,552,000 from RMB 503,080,000 in the previous year, reflecting the company's commitment to innovation[4]. - Research and development expenses for the year were approximately RMB 546,552,000, representing 4.0% of the group's revenue, up from 3.8% in 2021[52]. - The group obtained 123 new patents in China and has 171 patents pending as of December 31, 2022[51]. - The company is actively increasing internal R&D investment to accelerate product development and market access, responding to the changing economic cycle and challenges faced by startups[71]. Revenue Breakdown - The medical device segment generated revenue of RMB 6,859,029 thousand, accounting for approximately 50.4% of total revenue[16]. - The orthopedic products segment reported revenue of RMB 1,830,419 thousand, representing about 13.5% of total revenue[16]. - The interventional products segment achieved revenue of RMB 1,726,167 thousand, contributing around 12.7% to total revenue[16]. - The pharmaceutical packaging products segment generated revenue of RMB 2,105,432 thousand, which is approximately 15.4% of total revenue[16]. - The blood management products segment reported revenue of RMB 1,097,960 thousand, making up about 8.1% of total revenue[16]. - Revenue from clinical care medical devices reached RMB 4,726,552,000, up from RMB 4,632,034,000 in the previous year, indicating a growth of 2.0%[25]. - Revenue from blood management products increased by 12.4% year-on-year, contributing to overall revenue growth[56]. - The orthopedic business revenue decreased by 13.9% to approximately RMB 1,830,419,000 in 2022[50]. - The interventional business recorded revenue of approximately RMB 1,938,237,000, a growth of 9.3% compared to the previous year[50]. Operational Highlights - The company employed a total of 12,122 employees, an increase from 11,123 in the previous year, with significant growth in the production department[57]. - The company maintained a strong cash and bank balance of approximately RMB 6,862,278,000 as of December 31, 2022[62]. - The company achieved a net cash flow from operating activities of approximately RMB 2,214,574,000, reflecting good cash flow conditions[62]. - The company has a capital commitment of approximately RMB 1,299,231,000 for acquisitions and property purchases as of December 31, 2022[66]. - The company has pledged bank deposits of RMB 694,084,000 to secure short-term loans and credit facilities[67]. Corporate Governance - The company has confirmed the independence of its non-executive directors as of March 30, 2023, in compliance with listing rules[85]. - The company has adhered to the corporate governance code throughout the year ending December 31, 2022, ensuring transparency and protection of shareholder rights[86]. - The company is committed to maintaining high levels of corporate governance to enhance shareholder value[86]. - The annual general meeting is scheduled for May 29, 2023, with a suspension of share transfer registration from May 23 to May 29, 2023[86]. Strategic Initiatives - The company aims to enhance its market share and industry competitiveness through product upgrades and cost control measures[69]. - The company is expanding its product portfolio in clinical nursing, including digital products to improve nursing management quality[70]. - The company is focusing on developing international clients to capture overseas market opportunities in the pharmaceutical packaging sector[70]. - The company established Baiqing Energy to enter the hospital energy management sector, aiming for energy efficiency and carbon reduction[71]. - The company promotes collaboration and resource sharing across its segments, fostering flexibility and vitality, and is actively cultivating new business areas for growth[73]. - The company has developed an excellent marketing system tailored to the Chinese market, particularly through a robust hospital direct sales network, enhancing channel advantages[75]. - The management is confident in sustainable growth for 2023 and beyond, supported by a strategic layout across diverse business areas and high-quality products[76]. - The company is committed to a three-pronged operational strategy focusing on "platformization," "internationalization," and "digitalization," supported by "talent" and "innovation" strategies[75].
威高股份(01066) - 2022 - 年度业绩